Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
12.70
+0.33 (2.67%)
At close: Jun 15, 2026, 4:00 PM EDT
12.75
+0.05 (0.39%)
After-hours: Jun 15, 2026, 4:10 PM EDT
Atrium Therapeutics Revenue
Atrium Therapeutics had revenue of $19.64M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $36.68M. In the year 2025, Atrium Therapeutics had annual revenue of $18.62M with 70.85% growth.
Revenue (ttm)
$36.68M
Revenue Growth
+70.85%
P/S Ratio
5.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
217.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.62M | 7.72M | 70.85% |
| Dec 31, 2024 | 10.90M | 1.13M | 11.60% |
| Dec 31, 2023 | 9.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNA News
- 4 weeks ago - Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform - TheFly
- 4 weeks ago - Atrium Therapeutics initiated with an Outperform at Leerink - TheFly
- 4 weeks ago - Atrium Therapeutics Reports First Quarter 2026 Financial Results - PRNewsWire
- 7 weeks ago - Atrium Therapeutics earns $15M development milestone payment from Bristol Myers - TheFly
- 7 weeks ago - Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PRNewsWire
- 7 weeks ago - Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 3 months ago - Atrium Therapeutics initiated with an Overweight at Wells Fargo - TheFly
- 3 months ago - Atrium Therapeutics launches as newly independent, publicly traded company - TheFly